PDX-1 is a critically important transcription factor for the insulin promoter, is absent in glucotoxic islets, and, when transfected into glucotoxic ß-cells, improves insulin promoter activity.

A syndrome characterized by severe peptic ulcer disease, gastric acid hypersecretion, and non-beta islet cell tumors of the pancreas was first described by Zollinger and Ellison in 1955.

In type 1 diabetes, it also evades the autoimmune rejection of pancreatic beta cells. UP421 cells were transplanted with no immunosuppression, and the survival of the islet cells provides evidence ...

Last year, CellTrans claimed the first FDA approval for a cell therapy for type 1 diabetes, Lantidra (donislecel) consisting of insulin-producing islet beta cells taken from deceased donors.

Researchers at IISc Bengaluru discover potential drug-free treatment for diabetes by enhancing beta-cell function with small ...

Results of the study over four weeks after islet cell transplantation demonstrate the survival and function of pancreatic beta cells at each weekly blood draw, as measured by the presence of ...

Sana Biotechnology said a type 1 diabetes (T1D) patient received an allogeneic primary islet cell transplantation ... at 4 weeks showed pancreatic beta cell survival and function.

The Seattle-based biotech is evaluating UP421, a donor-derived allogeneic primary islet cell therapy ... that indicates if the transplanted beta cells are producing insulin, according to a ...

This is a useful study that seeks to address the role of the TET family of DNA demethylation enzymes in pancreatic beta cell senescence in the context of type 2 diabetes (T2DM). Although the concepts ...

The study identified no safety issues, and the HIP-modified islet cells evaded immune responses ... a person’s immune system attacks and destroys the beta cells. Today’s data, when combined ...